Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 9/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17004772 | 0.89 | HCK (0.35) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL17017528 | 0.89 | HCK (0.35) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL31086607 | 0.89 | HCK (0.35) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL17018876 | 0.87 | MAPK14 (0.39) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL17004776 | 0.87 | MAPK14 (0.48) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL18567054 | 0.86 | LRRK2 (0.41) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL28573504 | 0.85 | HCK (0.38) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL17014134 | 0.85 | ALDH1A1 (0.39) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL18567055 | 0.84 | HCK (0.37) | HCKMAPK12MAPK14SRCMEN1 | |
| SCHEMBL29711928 | 0.84 | MAPK14 (0.45) | HCKMAPK12MAPK14SRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | TOPIVERT PHARMA LTD. (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9624196-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-9447076-B2 | Inhibitor of p38 map kinase | RESPIVERT LTD. (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | HCK 553/4885MAPK12 37/4885MAPK14 16/4885 |
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAP3K1 | HCK 274/4885MAPK12 34/4885MAPK14 5/4885 |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPK4, MAPK8 | HCK 678/4885MAPK12 33/4885MAPK14 13/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | HCK 2965/4885MAPK12 13/4885MAPK14 4/4885 |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | HCK 812/4885MAPK12 27/4885MAPK14 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.